QUICK READ
Blue Earth Therapeutics, an Oxford-based startup, has raised £60m in a Series A round led by Soleus Capital. Founded by CEO David Gauden, the company focuses on developing innovative radioligand therapies aimed at treating prostate cancer. Its platform supports high-precision treatments that deliver targeted radiation to tumours while sparing surrounding healthy organs.
The company's solutions are already progressing through clinical trials, showing promise for improved patient outcomes in prostate cancer care. The new capital will support Phase 2 studies of advanced radiopharmaceuticals, accelerating research to differentiate their therapies from first-generation treatments. Current investors include Soleus Capital, with additional participation from Sands Capital Management, Bracco Imaging, Woodline Partners, and PBM Capital.